Zobrazeno 1 - 10
of 132
pro vyhledávání: '"Finn Bengtsson"'
Autor:
Ann-Charlotte Åkerblad, Finn Bengtsson, Margareta Holgersson, Lars von Knorring, Lisa Ekselius
Publikováno v:
Patient Preference and Adherence, Vol 2008, Iss default, Pp 379-386 (2009)
Ann-Charlotte Åkerblad1, Finn Bengtsson2, Margareta Holgersson3, Lars von Knorring1, Lisa Ekselius11Department of Neuroscience, Psychiatry, Uppsala University Hospital, Uppsala University, Uppsala, Sweden; 2Division of Clinical Pharmacology, Medicin
Externí odkaz:
https://doaj.org/article/8e8e0cf6fd6e4e45beb3b451ac8af9d8
Autor:
Björn Carlsson, Johan Ahlner, Finn Bengtsson, Fredrik C. Kugelberg, Ulrich Schmitt, Louise Karlsson, Christoph Hiemke
Publikováno v:
European Neuropsychopharmacology. 23:1636-1644
Background: According to both in vitro and in vivo data P-glycoprotein (P-gp) may restrict the uptake of several antidepressants into the brain, thus contributing to the poor success rate of current antidepressant therapies. The therapeutic activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c430acd171daa839651628f19bdb458
https://doi.org/10.1016/j.euroneuro.2013.01.003
https://doi.org/10.1016/j.euroneuro.2013.01.003
Autor:
Johan Ahlner, Martin Josefsson, Finn Bengtsson, Maria Kingbäck, Louise Karlsson, Fredrik C. Kugelberg, Björn Carlsson
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 53:583-590
A stereoselective method is described for simultaneous determination of the S- and R-enantiomers of venlafaxine and its three demethylated metabolites in human plasma and whole blood samples. This validated method involved LC/MS/MS with positive elec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bbac198df89adad733363b4070c33f5
https://doi.org/10.1016/j.jpba.2010.03.043
https://doi.org/10.1016/j.jpba.2010.03.043
Publikováno v:
Chirality. 23:172-177
The female Sprague-Dawley (SD) and Dark Agouti (DA) rats are considered the animal counterparts of the human extensive and poor metabolizer cytochrome P450 (CYP) 2D6 phenotypes, respectively. The aim of this work was to study possible rat strain diff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a9deedf664832e03e8399a27399110f
https://doi.org/10.1002/chir.20901
https://doi.org/10.1002/chir.20901
Publikováno v:
Acta Pharmacologica et Toxicologica. 59:211-214
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f62b4950188f836e1d1899bb3c23512d
https://doi.org/10.1111/j.1600-0773.1986.tb02746.x
https://doi.org/10.1111/j.1600-0773.1986.tb02746.x
Publikováno v:
Journal of Analytical Toxicology. 33:65-76
Citalopram is marketed as a racemate (50:50) mixture of the S(+)-enantiomer and R(-)-enantiomer and the active S(+)-enantiomer (escitalopram) that possess inhibitory effects. Citalopram was introduced in Sweden in 1992 and is the most frequently used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9239b987447af3c337eca31a0063ecbf
https://doi.org/10.1093/jat/33.2.65
https://doi.org/10.1093/jat/33.2.65
Autor:
Finn Bengtsson, Johan Ahlner, Michèle Jonzier-Perey, Pierre Baumann, Anna-Britta Lind, Margareta Reis, Marja-Liisa Dahl, Kerry Powell Golay
Publikováno v:
Clinical Pharmacokinetics. 48:63-70
Mirtazapine is a tetracyclic antidepressant drug available as a racemic mixture of S(+)- and R(−)-mirtazapine. These enantiomers have different pharmacological properties, and both contribute to the clinical and adverse effects of the drug. Cytochr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d96429818ef228579304a76f8b7c03d4
https://doi.org/10.2165/0003088-200948010-00005
https://doi.org/10.2165/0003088-200948010-00005
Publikováno v:
Therapeutic Drug Monitoring. 30:682-688
There is limited information on the pharmacokinetics ofziprasidone (ZIP) in naturalistic clinical settings. The objective of this study was to investigate the concentrations of ZIP and its active metabolite S-methyl-dihydroziprasidone (SMDZ), and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33f921bfbdcf4cf9a3f5fd5648d62b73
https://doi.org/10.1097/ftd.0b013e31818ac8ba
https://doi.org/10.1097/ftd.0b013e31818ac8ba
Publikováno v:
Neuropsychopharmacology. 34:585-592
Several studies suggest that serotonin reuptake inhibitors (SRIs) exert a more rapid effect when used for the treatment of symptoms such as anger and irritability then when used for depression, obsessive-compulsive disorder, or anxiety. In line with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::527fa3d90babfdb601c98da73082a8ef
https://doi.org/10.1038/npp.2008.86
https://doi.org/10.1038/npp.2008.86
Autor:
Finn Bengtsson, Margareta Holgersson, Ann-Charlotte Åkerblad, Lisa Ekselius, Lars von Knorring
Publikováno v:
Patient preference and adherence
Patient Preference and Adherence, Vol 2008, Iss default, Pp 379-386 (2009)
Patient Preference and Adherence, Vol 2008, Iss default, Pp 379-386 (2009)
Ann-Charlotte Åkerblad1, Finn Bengtsson2, Margareta Holgersson3, Lars von Knorring1, Lisa Ekselius11Department of Neuroscience, Psychiatry, Uppsala University Hospital, Uppsala University, Uppsala, Sweden; 2Division of Clinical Pharmacology, Medicin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c73fa494307ab61f9c916d5a6c300ebb
http://europepmc.org/articles/PMC2770387
http://europepmc.org/articles/PMC2770387